 EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant Both patients treated with EDIT-301 successfully engrafted and are free of vaso-occlusive events during the follow-up period First patient treated has a total hemoglobin level of 16.4 gdL and 45.4 fetal hemoglobin five months after ... The post Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patie... 